In: Molecular Neurobiology, 2005, vol. 32, no. 1, p. 59-72
|
In: Nephrology Dialysis Transplantation, 2012, vol. 27, no. 4, p. 1559-1568
|
In: Nephrology Dialysis Transplantation, 2005, vol. 20, no. 7, p. 1329-1335
|
In: American Journal of Physiology - Heart and Circulatory Physiology, 2009, vol. 296, p. H815-H822
Hexosamine biosynthetic pathway (HBP) accounts for some cardiovascular adverse effects of hyperglycemia. We investigated whether the HBP inhibitor azaserine protects against hyperglycemia-induced endothelial damage dependently of HBP. Human endothelial cells isolated from umbilical veins were exposed either to a high (30.5 mmol/l) or low concentration of glucose (5.5 mmol/l) for 4 days, followed...
|